Asset profile
Selinexor
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Myelofibrosis · Phase 3Endometrial Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 62 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Selinexor: this drug | Approved | Small molecule | XPO1 (exportin-1) | ||
| Eltanexor | Phase 1/2 | — | XPO1 (exportin-1) | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Imetelstat | Approved | Small molecule | Telomerase | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Linvoseltamab | Approved | Multispecific antibody | BCMA x CD3 |
…and 48 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(50 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
November 2026 (1)
Phase 2Diffuse Large B Cell LymphomaNot yet recruiting
Est. primary completion 2026-11-01 · NCT06652139 · CT.gov ↗
What to watch
December 2026 (5)
Phase 2Diffuse Large B-cell LymphomaActive not recruiting
Est. primary completion 2026-12 · NCT02227251 · CT.gov ↗
What to watch
Phase 2/3Relapsed/Refractory Diffuse Large B-cell LymphomaActive not recruiting
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
Phase 1/2NKTCL, SelinexorRecruiting
Est. primary completion 2026-12-01 · NCT06559553 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06822972 · CT.gov ↗
What to watch
Phase 2LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02436707 · CT.gov ↗
What to watch
2027 (26)
January 2027 (2)
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-04-01 · NCT06225310 · CT.gov ↗
What to watch
Phase 2Untreated Adult Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-18 · NCT02835222 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma …Recruiting
Est. primary completion 2027-05-01 · NCT05333458 · CT.gov ↗
What to watch
Phase 1/2Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKLRecruiting
Est. primary completion 2027-05-30 · NCT06966154 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell TransplantationActive not recruiting
Est. primary completion 2027-06-30 · NCT07094464 · CT.gov ↗
What to watch
Phase 1/2Malignant GliomaRecruiting
Est. primary completion 2027-06-30 · NCT05099003 · CT.gov ↗
What to watch
Phase 1/2Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated GlioblastomaRecruiting
Est. primary completion 2027-06-30 · NCT05432804 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-07 · NCT07479979 · CT.gov ↗
What to watch
Phase 2Lymphoma, Extranodal NK-T-CellNot yet recruiting
Est. primary completion 2027-07-01 · NCT06573138 · CT.gov ↗
What to watch
Phase 2LymphomaNot yet recruiting
Est. primary completion 2027-07-01 · NCT06573151 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Langerhans Cell Histiocytosis (LCH)Active not recruiting
Est. primary completion 2027-08-01 · NCT07204041 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (1)
Early phase / not applicableMyeloid TumorsNot yet recruiting
Est. primary completion 2027-10-01 · NCT07632170 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast CancersRecruiting
Est. primary completion 2027-11 · NCT05035745 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1/2Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma …Active not recruiting
Est. primary completion 2027-12 · NCT03147885 · CT.gov ↗
What to watch
Phase 2Extensive Stage Lung Small Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07172412 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-12 · NCT07138209 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 2Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07405255 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT07437170 · CT.gov ↗
What to watch
Phase 2Extranodal NK/T-cell LymphomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07554482 · CT.gov ↗
What to watch
2028 (12)
January 2028 (4)
Phase 1/2Peripheral T-cell Lymphoma (PTCL)Not yet recruiting
Est. primary completion 2028-01 · NCT07706959 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT06744894 · CT.gov ↗
What to watch
Early phase / not applicableAML, Refractory, RelapsedRecruiting
Est. primary completion 2028-01-30 · NCT06265545 · CT.gov ↗
What to watch
February 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
Phase 2Light-chain Cardiac AmyloidosisNot yet recruiting
Est. primary completion 2028-02-01 · NCT07743957 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
March 2028 (2)
April 2028 (1)
Phase 1/2Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)Active not recruiting
Est. primary completion 2028-04-30 · NCT07779031 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-04-30 · NCT07200102 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid TumorRecruiting
Est. primary completion 2029-08-01 · NCT05985161 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2NK T-Cell LymphomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07276698 · CT.gov ↗
What to watch
2030 (2)
2034 (1)
June 2034 (1)
Phase 1/2Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma …Recruiting
Est. primary completion 2034-06 · NCT06239272 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.